SecBot SecBot
8-K ·Filed Apr 28, 2026

MDGL

MADRIGAL PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001628280-26-027956
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading implications. Monitor the annual meeting on June 17, 2026 for any unexpected proxy contest or changes to board composition.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$518.58
T+0 close · Apr 28, 2026 · via day close
Latest settled
+5.00%
T+60 · $544.51
Vs SPY
+0.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $518.58entry
  2. T+1 · 7mo ago −0.23%α −1.25% · $517.39
  3. T+5 · 7mo ago +4.08%α +0.97% · $539.73
  4. T+20 · 6mo ago −0.51%α −6.55% · $515.96
  5. T+60 · 4mo ago +5.00%α +0.89% · $544.51

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Madrigal Pharmaceuticals reclassified two directors (Julian Baker and Daniel Brennan) to Class I to balance board classes ahead of the June 17, 2026 annual meeting. This is a routine administrative change with no material impact on operations or strategy.

Key Facts

  • Julian C. Baker and Daniel J. Brennan reclassified as Class I directors effective April 22, 2026.
  • Reclassification balances board classes; no change in committee assignments.
  • Both directors, along with James Daly, are nominated for re-election at the June 17, 2026 annual meeting.

Financial Impact

No financial impact from this board reorganization.

Risk Factors

  • Risk of contested director elections if shareholders oppose nominees, though currently no indication of opposition.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-027956
Document: 0001628280-26-027956-index-headers.html0001628280-26-027956
Document: 0001628280-26-027956-index.html0001628280-26-027956
Document: 0001628280-26-027956.txt0001628280-26-027956

Track record

18 reports on MDGL

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $424.08 Now $423.96 −0.03% settles Nov 23
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  3. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  4. Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  5. Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  6. Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  7. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  8. Nov 3, 202613d ago 8-K Bullish 7/10 No price data
  9. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
  10. Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 9h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026